Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading Volume – Here’s Why

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) saw unusually-high trading volume on Friday . 913,268 shares were traded during mid-day trading, an increase of 50% from the previous session’s volume of 610,285 shares.The stock last traded at $22.43 and had previously closed at $22.10.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ADPT shares. JPMorgan Chase & Co. lowered their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday. BTIG Research restated a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Finally, Morgan Stanley lifted their price objective on Adaptive Biotechnologies from $18.00 to $20.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Adaptive Biotechnologies Stock Performance

The company has a market capitalization of $3.67 billion, a PE ratio of -69.45 and a beta of 2.07. The company’s 50-day moving average is $17.59 and its 200 day moving average is $16.22.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. During the same period in the previous year, the company earned ($0.20) earnings per share. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Insider Activity

In related news, insider Harlan S. Robins sold 386,240 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.01, for a total value of $8,501,142.40. Following the transaction, the insider directly owned 1,019,658 shares of the company’s stock, valued at approximately $22,442,672.58. This represents a 27.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 30,941 shares of the stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $14.66, for a total value of $453,595.06. Following the sale, the chief operating officer owned 395,146 shares in the company, valued at approximately $5,792,840.36. This represents a 7.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 920,545 shares of company stock valued at $18,588,281 in the last quarter. Insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors have recently modified their holdings of the business. Ameriprise Financial Inc. raised its position in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP purchased a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $65,942,000. Geode Capital Management LLC boosted its holdings in shares of Adaptive Biotechnologies by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after acquiring an additional 110,825 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Adaptive Biotechnologies by 3.3% in the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock worth $51,670,000 after acquiring an additional 102,362 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.